TrialCancer discovery2022
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Kenneth F Grossmann et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
76 papers cite itlatest 60 shown
this paperpooled ittrialcites it